Pathobiology of virus glycosylation: Implications to disease and prospects for treatment

Future Virology

Volumn 2, Issue 6, 2007, Pages 615-623

  Vigerust, David J ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Antivirals; Glycosylation; Pharmacognosy; Virus

Indexed keywords

1 DEOXYMANNONOJIRIMYCIN; CD4 ANTIGEN; CHLOROQUINE; CONCANAVALIN A; CYANOVIRIN N; GALANTHUS NIVALIA EXTRACT; GLYCOPROTEIN GP 120; GLYCOSIDASE INHIBITOR; NEUTRALIZING ANTIBODY; OLIGOSACCHARIDE; PLANT EXTRACT; PLANT LECTIN; PRADIMICIN A; PROTEINASE; SURFACTANT PROTEIN D; UNCLASSIFIED DRUG; URTICA DIOICA EXTRACT; VIRUS ENVELOPE PROTEIN; VIRUS GLYCOPROTEIN; VIRUS HEMAGGLUTININ; VIRUS SIALIDASE;

ANTIVIRAL ACTIVITY; DENGUE VIRUS; FLAVIVIRUS; GALANTHUS; GALANTHUS NIVALIA; GLYCOSYLATION; HENDRA VIRUS; HEPATITIS C VIRUS; HEPATITIS VIRUS; HOST; HOST CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RESPONSE; IMMUNE SYSTEM; INFLUENZA VIRUS; INHIBITION KINETICS; LIFE CYCLE; NONHUMAN; ORTHOMYXOVIRUS; PARAMYXOVIRUS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN INTERACTION; PROTEIN MODIFICATION; PROTEIN PROCESSING; PROTEIN TRANSPORT; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RETROVIRUS; REVIEW; SARS CORONAVIRUS; URTICA DIOICA; VIRUS CELL INTERACTION; VIRUS INFECTION; VIRUS INFECTIVITY; VIRUS REPLICATION; VIRUS SURVIVAL; VIRUS TRANSMISSION; VIRUS VIRULENCE; WEST NILE FLAVIVIRUS;

RESPIRATORY SYNCYTIAL VIRUS; SARS CORONAVIRUS; WEST NILE VIRUS;

EID: 36348969551     PISSN: 17460794     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460794.2.6.615     Document Type: Review

References (86)

1. Mondotte JA, Lozach PY, Amara A, Gamarnik AV: Essential role of Dengue virus envelope protein N glycosylation at asparagine-67 during viral propagation. J. Virol. 81, 7136-7148 (2007).
2. Korber B, Gaschen B, Yusim, K, Thakallapally R, Kesmir C, Detours V: Evolutionary and immunological implications of contemporary HIV-1 variation. Br. Med. Bull. 58, 19-42 (2001).
3. Wei X, Decker JM, Wang S et al.: Antibody neutralization and escape by HIV-1. Nature 422, 307-312 (2003).
4. Land A, Braakman I: Folding of the human immunodeficiency virus type 1 envelope glycoprotein in the endoplasmic reticulu. Biochimie 83, 783-790 (2001).
5. Slater-Handshy T, Droll DA, Fan X, Di Bisceglie AM, Chambers TJ: HCV E2 glycoprotein: mutagenesis of N-linked glycosylation sites and its effects on E2 expression and processing. Virology 319, 36-48 (2004).
6. Meunier JC, Foumillier A, Choukhi A et al.: Analysis of the glycosylation sites of hepatitis C virus (HCV) glycoprotein E1 and the influence of E1 glycans on the formation of the HCV glycoprotein complex. J. Gen. Virol. 80 (Pt 4), 887-896 (1999).
7. Wagner R, Wolff T, Herwig A, Pleschka S, Klenk HD: Interdependence of hemagglutinin glycosylation and neuraminidase as regulators of influenza virus growth: a study by reverse genetics. J. Virol. 74, 6316-6323 (2000).
8. Klenk HD, Wagner R, Heuer D, Wolff T: Importance of hemagglutinin glycosylation for the biological functions of influenza virus. Virus Res. 82, 73-75 (2002).
9. Baigent SJ, McCauley JW: Glycosylation of haemagglutinin and stalk-length of neuraminidase combine to regulate the growth of avian influenza viruses in tissue culture. Virus Res. 79, 177-185 (2001).
10. Tsuchiya E, Sugawara K, Hongo S, Matsuzaki Y, Muraki Y, Nakamura K: Role of overlapping glycosylation sequons in antigenic properties, intracellular transport and biological activities of influenza A/H2N2 virus haemagglutinin. J. Gen. Virol. 83, 3067-3074 (2002).
11. Tsuchiya E, Sugawara K, Hongo S et al.: Effect of addition of new oligosaccharide chains to the globular head of influenza A/H2N2 virus haemagglutinin on the intracellular transport and biological activities of the molecule. J. Gen. Virol. 83, 1137-1146 (2002).
12. Abe Y, Takashita E, Sugawara K, Matsuzaki Y, Muraki Y, Hongo S: Effect of the addition of oligosaccharides on the biological activities and antigenicity of influenza A/H3N2 virus hemagglutinin. J. Virol. 78, 9605-9611 (2004).
13. Kaverin NV, Rudeva IA, Ilyushina NA et al.: Structure of antigenic sites on the haemagglutinin molecule of H5 avian influenza virus and phenotypic variation of escape mutants. J. Gen. Virol. 83, 2497-2505 (2002).
14. Daniels R, Kurowski B, Johnson AE, Hebert DN: N-linked glycans direct the cotranslational folding pathway of influenza hemagglutinin. Mol. Cell 11, 79-90 (2003).
15. Skehel JJ, Wiley DC: Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu. Rev. Biochem. 69, 531-569 (2000).
16. Vigerust DJ, Ulett KB, Boyd KL, Madsen J, Hawgood S, McCullers JA: N-Linked glycosylation attenuates H3N2 influenza viruses. J. Virol. 81, 8593-8600 (2007).
17. Deshpande KL, Fried VA, Ando M, Webster RG: Glycosylation affects cleavage of an H5N2 influenza virus hemagglutinin and regulates virulence. Proc. Natl Acad. Sci. USA 84, 36-40 (1987).
18. Zambon MC: Epidemiology and pathogenesis of influenza. J. Antimicrob. Chemother. 44(Suppl. B), S3-S9 (1999).
19. Martin-Gallardo A, Fleischer E, Doyle SA et al.: Expression of the G glycoprotein gene of human respiratory syncytial virus in Salmonella typhimurium. J. Gen. Virol. 74(Pt 3), 453-458 (1993).
20. Collins PL, Mottet G: Oligomerization and post-translational processing of glycoprotein G of human respiratory syncytial virus: altered O-glycosylation in the presence of brefeldin A. J. Gen. Virol. 73(Pt 4), 849-863 (1992).
21. Aguilar HC, Matreyek KA, Filone CM et al.: N-glycans on Nipah virus fusion protein protect against neutralization but reduce membrane fusion and vital entry. J. Virol. 80, 4878-4889 (2006).
22. Moll M, Kaufmann A, Maisner A: Influence of N-glycans on processing and biological activity of the Nipah virus fusion protein. J. Virol. 78, 7274-7278 (2004).
23. Bossart KN, Crameri G, Dimitrov AS et al.: Receptor binding, fusion inhibition, and induction of cross-reactive neutralizing antibodies by a soluble G glycoprotein of Hendra virus. J. Virol. 79, 6690-6702 (2005).
24. Oostra M, de Haan CA, de Groot RJ, Rottier PJ: Glycosylation of the severe acute respiratory syndrome coronavirus triple-spanning membrane proteins 3a and M. J. Virol. 80, 2326-2336 (2006).
25. Schowalter RM, Smith SE, Dutch RE: Characterization of human metapneumovirus F protein-promoted membrane fusion: critical roles for proteolytic processing and low Ph. J. Virol. 80(22), 10931-10941 (2006).
26. Korber B, Muldoon M, Theiler J et al.: Timing the ancestor of the HIV-1 pandemic strains. Science 288, 1789-1796 (2000).
27. Fenouillet E, Gluckman JC, Bahraoui E: Role of N-linked glycans of envelope glycoproteins in infectivity of human immunodeficiency virus type 1. J. Virol. 64, 2841-2848 (1990).
28. Montefiori DC, Robinson WE Jr, Mitchell WM: Role of protein N-glycosylation in pathogenesis of human immunodeficiency virus type 1. Proc. Natl Acad. Sci. USA 85, 9248-9252 (1988).
29. Wolk T, Schreiber M: N-Glycans in the gp120 V1/V2 domain of the HIV-1 strain NL4-3 are indispensable for viral infectivity and resistance against antibody neutralization. Med. Microbiol. Immunol. (Berl) 195, 165-172 (2006).
30. Wolk T, Schreiber M: N-Glycans in the gp120 V1/V2 domain ofthe HIV-1 strain NL4-3 are indispensable for vital infectivity and resistance against antibody neutralization. Med. Microbiol. Immunol. 195, 165-172 (2006).
31. Bernstein HB, Tucker SP, Hunter E, Schutzbach JS, Compans RW: Human immunodeficiency virus type 1 envelope glycoproteinis modified by O-linked oligosaccharides. J. Virol. 68, 463-468 (1994).
32. Paulson JC: Glycoproteins: what are the sugar chains for? Trends Biochem. Sci. 14, 272-276 (1989).
33. Burton DR: Antibodies, viruses and vaccines. Nat. Rev. Immunol. 2, 706-713 (2002).
34. Sanders RW, Venturi M, Schiffner L et al.: The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. J. Virol. 76, 7293-7305 (2002).
35. Manrique A, Rusert P, Joos B et al.: In vivo and in vitro escape from neutralizing antibodies 2G12, 2F5, and 4E10. J. Virol. 81, 8793-8808 (2007).
36. Calarese DA, Lee HK, Huang CY et al.: Dissection of the carbohydrate specificity of the broadly neutralizing and-HIV-1 antibody 2G12. Proc. Natl Acad. Sci. USA 102, 13372-13377 (2005).
37. Calarese DA, Scanlan CN, Zwick MB et al.: Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science 300, 2065-2071 (2003).
38. Geijtenbeek TB, van Kooyk Y: DC-SIGN: a novel HIV receptor on DCs that mediates HIV-1 transmission. Curr. Top Microbiol. Immunol. 276, 31-54 (2003).
39. Vigerust DJ, Egan BS, Shepherd VL: HIV-1 Nef mediates post-translational down-regulation and redistribution of the mannose receptor. J. Leukoc. Biol. 77, 522-534 (2005).
40. Trujillo JR, Rogers R, Molina RM et al.: Noninfectious entry of HIV-1 into peripheral and brain macrophages mediated by the mannose receptor. Poc. Natl Acad. Sci. USA 104, 5097-5102 (2007).
41. Frost SD, Wrin T, Smith DM et al.: Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection. Proc. Natl Acad. Sci. USA 102, 18514-18519 (2005).
42. Malenbaum SE, Yang D, Cavacini L, Posner M, Robinson J, Cheng-Mayer C: The N-terminal V3 loop glycan modulates the interaction of clade A and B human immunodeficiency virus type 1 envelopes with CD4 and chemokine receptors. J. Virol. 74, 11008-11016 (2000).
43. Simmonds P: Genetic diversity and evolution of hepatitis C virus - 15 years on. J. Gen. Virol. 85, 3173-3188 (2004).
44. Shirato K, Miyoshi H, Goto A et al.: Viral envelope protein glycosylation is a molecular determinant of the neuroinvasiveness of the New York strain of West Nile virus. J. Gen. Virol. 85, 3637-3645 (2004).
45. Scherret JH, Mackenzie JSs, Khromykh AA, Hall RA: Biological significance of glycosylation of the envelope protein of Kunjin virus. Ann. NY Acad. Sci. 951, 361-363 (2001).
46. Beasley DW, Whiteman MC, Zhang S et al.: Envelope protein glycosylation status influences mouse neuroinvasion phenotype of genetic lineage 1 West Nile virus strains. J. Virol. 79, 8339-8347 (2005).
47. Lad VJ, Shende VR, Gupta AK, Koshy AA, Roy A: Effect of tunicamycin on expression of epitopes on Japanese encephalitis virus glycoprotein E in porcine kidney cells. Acta Virol. 44, 359-364 (2000).
48. Hanna SL, Pierson TC, Sanchez MD, Ahmed AA, Murtadha MM, Doms RW: N-linked glycosylation of West Nile virus envelope proteins influences particle assembly and infectivity. J. Virol. 79, 13262-13274 (2005).
49. Bryant JE, Calvert AE, Mesesan K et al.: Glycosylation of the Dengue 2 virus E protein at N67 is critical for virus growth in vitro but not for growth in intrathoracically inoculated Aedes aegypti mosquitoes. Virology 366(2), 415-423 (2007).
50. Crabtree MB, Kinney RM, Miller BR: Deglycosylation of the NS1 protein of Dengue 2 virus, strain 16681: construction and characterization of mutant viruses. Arch Virol. 150, 771-786 (2005).
51. Goffard A, Callens N, Bartosch B et al.: Role of N-linked glycans in the functions of hepatitis C virus envelope glycoproteins. J. Virol. 79, 8400-8499 (2005).
52. Beyene A, Basu A, Meyer K, Ray R: Influence of N-linked glycans on intracellular transport of hepatitis C virus E1 chimeric glycoprotein and its role in pseudotype virus infectivity. Virology 324, 273-285 (2004).
53. Goffard A, Dubuisson J: Glycosylation of hepatitis C virus envelope proteins. Biochimie 85, 295-301 (2003).
54. Falkowska E, Kajumo F, Garcia E, Reinus J, Dragic T: Hepatitis C virus envelope glycoprotein E2 glycans modulate entry, CD81 binding, and neutralization. J. Virol. 81, 8072-8079 (2007).
55. Witvrouw M, Fikkert V, Hantson A et al.: Resistance of human immunodeficiency virus type 1 to the high-mannose binding agents cyanovirin N and concanavalin A. J. Virol. 79, 7777-7784 (2005).
56. Williams DC, Jr., Lee JY, Cai M, Bewley CA, Clore GM: Crystal structures of the HIV-1 inhibitory cyanobacterial protein MVL free and bound to Man3GlcNAc2: structural basis for specificity and high-affinity binding to the core pentasaccharide from N-linked oligomannoside. J. Biol. Chem. 280, 29269-29276 (2005).
57. Balzarini J, Van Herrewege Y, Vermeire K, Vanham G, Schols D: Carbohydrate-binding agents efficiently prevent dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin (DC-SIGN)-directed HIV-1 transmission to T lymphocytes. Mol. Pharmacol. 71, 3-11 (2007).
58. O'Keefe BR, Smee DF, Turpin JA et al.: Potent anti-influenza activity of cyanovirin-N and interactions with viral hemagglutinin. Antimicrob. Agents Chemother. 47, 2518-2525 (2003).
59. Balzarini J: Carbohydrate-binding agents: a potential future cornerstone for the chemotherapy of enveloped viruses? Antivir. Chem. Chemother. 18, 1-11 (2007).
60. Helle F, Wychowski C, Vu-Dac N, Gustafson KR, Voisset C, Dubuisson J: Cyanovirin-N inhibits hepatitis C virus entry by binding to envelope protein glycans. J. Biol. Chem. 281, 25177-25183 (2006).
61. Bertaux C, Daelemans D, Meertens L et al.: Entry of hepatitis C virus and human immunodeficiency virus is selectively inhibited by carbohydrate-binding agents but not by polyanions. Virology 366(1), 40-50 (2007).
62. Keyaerts E, Vijgen L, Pannecouque C et al.: Plant lectins are potent inhibitors of coronaviruses by interfering with two targets in the viral replication cycle. Antiviral Res. 75, 179-187 (2007).
63. van der Meer FJ, de Haan CA, Schuurman NM et al.: Antiviral activity of carbohydrate-binding agents against Nidovirales in cell culture. Antiviral Res. 76, 21-29 (2007).
64. Romanelli F, Smith KM, Hoven AD: Chloroquine and hydroxydiloroquine as inhibitors of human immunodeficiency virus (HIV-1) activity. Curr. Pharm. Des. 10, 2643-2648 (2004).
65. Boelaert JR, Sperber K, Pierre J: Chloroquine exerts an additive in vitro anti-HIV type 1 effect when associated with didanosine and hydroxyurea. AIDS Res. Hum. Retroviruses 15, 1241-1247 (1999).
66. Sperber K, Louie M, Kraus T et al.: Hydroxychloroquine treatment of patients with human immunodeficiency virus type 1. Clin. Ther. 17, 622-636 (1995).
67. Paton NI, Aboulhab J: Hydroxychloroquine, hydroxyurea and didanosine as initial therapy for HIV-infected patients with low viral load: safety, efficacy and resistance profile after 144 weeks. HIV Med. 6, 13-20 (2005).
68. + T-lymphocytes. Retrovirology 4, 6 (2007).
69. Vincent MJ, Bergeron E, Benjannet S et al.: Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol. J. 2, 69 (2005).
70. De Clercq E: Potential antivirals and antiviral strategies against SARS coronavirus infections. Expert Rev. Anti Infect. Ther. 4, 291-302 (2006).
71. Keyaerts E, Vijgen L, Maes P, Neyts J, Van Ranst M: In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine. Biochem. Biophys. Res. Commun. 323, 264-268 (2004).
72. Di Trani L, Savarino A, Campitelli L et al.: Different pH requirements are associated with divergent inhibitory effects of chloroquine on human and avian influenza A viruses. Virol. J. 4, 39 (2007).
73. Ooi EE, Chew JS, Loh JP, Chua RC: In vitro inhibition of human influenza A virus replication by chloroquine. Virol. J. 3, 39 (2006).
74. Savarino A, Di Trani L, Donatelli I, Cauda R, Cassone A: New insights into the antiviral effects of chloroquine. Lancet Infect. Dis. 6, 67-69 (2006).
75. Chapel C, Garcia C, Bartosch B et al.: Reduction of the infectivity of hepatitis C virus pseudoparticles by incorporation of misfolded glycoproteins induced by glucosidase inhibitors. J. Gen. Virol. 88, 1133-1143 (2007).
76. Tanaka Y, Kato J, Kohara M, Galinski MS: Antiviral effects of glycosylation and glucose trimming inhibitors on human parainfluenza virus type 3. Antiviral Res. 72, 1-9 (2006).
77. Wu SF, Lee CJ, Liao CL, Dwek RA, Zitzmann N, Lin YL: Antiviral effects of an iminosugar derivative on flavivirus infections. J. Virol. 76, 3596-3604 (2002).
78. Balzarini J: The alpha(1,2)-mannosidase I inhibitor 1-deoxymannojirimycin potentiates the antiviral activity of carbohydrate-binding agents against wildtype and mutant HIV-1 strains containing glycan deletions in gp120. FEBS Lett 581, 2060-2064 (2007).
79. Hart ML, Saifuddin M, Spear GT: Glycosylation inhibitors and neuraminidase enhance human immunodeficiency virus type 1 binding and neutralization by mannose-binding lectin. G. Gen. Virol. 84, 353-360 (2003).
80. Dwek RA, Butters TD, Platt FM, Zitzmann N: Targeting glycosylation as a therapeutic approach. Nat. Rev. Drug Discov. 1, 65-75 (2002).
81. Furmanek A, Hofsteenge J: Protein C-mannosylation: facts and questions. Acta Biochim. Pol. 47, 781-789 (2000).
82. Falzarano D, Krokhin O, Van Domselaar G et al.: Ebola sGP-the first viral glycoprotein shown to be C-mannosylated. Virology (Epub ahead of print) (2007).
83. Cambi A, de Lange F, van Maarseveen NM et al.: Microdomains of the C-type lectin DC-SIGN are portals for virus entry into dendritic cells. J. Cell Biol. 164, 145-155 (2004).
84. Cambi A, Figdor CG: Dual function of C-type lectin-like receptors in the immune system. Curr. Opin. Cell Biol. 15, 539-546 (2003).
85. Reading PC, Miller JL, Anders EM: Involvement of the mannose receptor in infection of macrophages by influenza virus. J. Virol. 74, 5190-5197 (2000).
86. Nguyen DG, Hildreth JE: Involvement of macrophage mannose receptor in the binding and transmission of HIV by macrophages. Eur. J. Immunol. 33, 483-493 (2003).